Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 57

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 57
---
 Physicians. She has specialist accreditation in Pharmaceutical Medicine from the UK General Medical Council and is a Fellow of the Faculty of Pharmaceutical Medicine in the UK. Dr. Rolfe was selected to serve on our board of directors based on her experience in leading drug discovery and development of therapeutics. Vote Required; Board Recommendation The plurality of votes of the shares present or represented by proxy and entitled to vote at the Annual Meeting will be required to approve this proposal. Abstentions and broker non -voteswill have no effect on the outcome of this proposal.

| THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE ELECTION OF EACH OF MICHAEL BYRNES AND LINDSEY ROLFE AS THE CLASS I DIRECTORS, TO SERVE FOR A THREE-YEAR TERM ENDING AT THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD IN 2028. |     | ü |

Directors Continuing in Office The following table and narrative information identify our directors continuing in office, and sets forth their principal occupation and business experience during the last five years and their ages as of April1, 2025.

| Name             |     | Age |     | Title                                       |     | Class and Year in 
 Which Term        
 Will Expire       |     | Director 
    Since |
| Brian G. Atwood  |     |  72 |     | Director                                    |     | Class II – 2026   |     |     2024 |
| Kathleen LaPorte |     |  63 |     | Director                                    |     | Class II – 2026   |     |     2024 |
| Shami Patel      |     |  56 |     | Director                                    |     | Class III – 2027  |     |     2024 |
| Chris Ehrlich    |     |  55 |     | Chairman, Chief Executive Officer, Director |     | Class III – 2027  |     |     2024 |

Class II Directors (Term Expires at 2026 Annual Meeting) Brian G. Atwoodpreviously served as Chairman and Chief Executive Officer of CERo from February 2024 to September 2024, and previously served as Chairman of PBAX from October 2021 until the closing of the Business Combination in February 2024. Mr. Atwood serves as a Managing Director for Versant Ventures, a healthcare -focusedventure capital firm that he co -foundedin 1999